Bezos, Elon Musk and Zuckerberg Betting Big on S.C.G.
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More
Gregory M. Glenn, insider at Novavax
Gregory M. Glenn Insider Alerts

Get notified the next time Gregory M. Glenn buys or sells Novavax stock. Enter your email address below to get our daily insider buying and selling report.

Gregory M. Glenn Insider Information

Insider of Novavax
Dr. Glenn is the president of research and development and leads the discovery, clinical, and regulatory teams. He has spent 28 years in the design and development of vaccines, vaccine delivery, and adjuvants. He has led the development of products from concept to late-stage clinical development, including COVID-19, RSV, recombinant adjuvanted seasonal and pandemic influenza vaccines, Ebola, and an Enterotoxigenic E. coli vaccine patch, and participated in other programs including the development of a malaria vaccine. He is the cofounder of IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008. He worked for Intercell from 2008 to 2010. He is the coauthor of more than 100 peer-reviewed scientific publications. Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into commercial vaccine development in 1997. Dr. Glenn received a bachelor of arts degree in biology and chemistry from Whitman College in Washington and a doctor of medicine degree from Oral Roberts University School of Medicine in Oklahoma.

What is Gregory M. Glenn's net worth?

The estimated net worth of Gregory M. Glenn is at least $387,866.30 as of September 15th, 2021. Dr. Glenn owns 4,582 shares of Novavax stock worth more than $387,866 as of January 22nd. This net worth estimate does not reflect any other assets that Dr. Glenn may own. Learn More.

What is Gregory M. Glenn's salary?

As the Insider of Novavax, Inc., Dr. Glenn earned a total compensation package of $24,923,376.00 in 2020. Dr. Glenn earned a salary of $483,443.00, stock awards of $1,206,210.00, options awards of $22,859,741.00, non-equity compensation of $362,582.00, and other compensation of $11,400.00.

How do I contact Gregory M. Glenn?

The corporate mailing address for Dr. Glenn and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]

Has Gregory M. Glenn been buying or selling shares of Novavax?

Gregory M. Glenn has not been actively trading shares of Novavax over the course of the past ninety days. Most recently, Gregory M. Glenn sold 1,183 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $229.34, for a transaction totalling $271,309.22. Following the completion of the sale, the insider now directly owns 4,582 shares of the company's stock, valued at $1,050,835.88.

Who are Novavax's active insiders?

Novavax's insider roster includes Stanley Erck (CEO), Gregory Glenn (Insider), John Herrmann, II (EVP), Rachel King (Director), David Mott (Director), and John Trizzino (CFO).

Are insiders buying or selling shares of Novavax?

During the last twelve months, Novavax insiders bought shares 1 times. They purchased a total of 700 shares worth more than $97,748.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 60 times. They sold a total of 434,696 shares worth more than $85,799,833.67. The most recent insider tranaction occured on January, 3rd when EVP John A Herrmann III sold 5,000 shares worth more than $704,550.00. Insiders at Novavax own 2.1 % of the company.

Information on this page was last updated on 1/3/2022.

Gregory M. Glenn Insider Trading History at Novavax

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Sell1,183$229.34$271,309.224,582View SEC Filing Icon  
8/31/2021Sell1,386$239.87$332,459.825,394View SEC Filing Icon  
7/20/2021Sell2,409$215.43$518,970.875,101View SEC Filing Icon  
7/15/2021Sell5,654$179.45$1,014,610.303,361View SEC Filing Icon  
6/17/2021Sell2,411$183.28$441,888.083,434View SEC Filing Icon  
1/31/2020Buy1,250$3.86$4,825.00View SEC Filing Icon  
7/31/2018Buy13,007$0.88$11,446.16View SEC Filing Icon  
1/31/2018Buy12,784$0.88$11,249.92View SEC Filing Icon  
1/31/2016Buy2,369$4.38$10,376.22View SEC Filing Icon  
8/18/2015Sell15,000$13.52$202,800.001,158View SEC Filing Icon  
See Full Table

Gregory M. Glenn Buying and Selling Activity at Novavax

This chart shows Gregory M. Glenn's buying and selling at Novavax by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Novavax Company Overview

Novavax logo
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More

Today's Range

Now: $84.65
Low: $84.55
High: $90.98

50 Day Range

MA: $161.55
Low: $84.65
High: $217.97

2 Week Range

Now: $84.65
Low: $84.55
High: $331.68

Volume

5,722,051 shs

Average Volume

6,366,397 shs

Market Capitalization

$6.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17
5 Tech Stocks to Buy Immediately
Eric Fry, one of America's top Investment Strategists, provides his latest report 5 Top Stocks for 2022.

You can't afford to miss out on the once in a decade chance to buy after the recent dip in the markets.
Download this hot-off-the-presses research report now. It’s yours FREE.